KEY INFORMATION FOR STARTING FIRMAGON

What to know and expect from your treatment



FIRMAGON® (degarelix for injection) is a prescription medicine used in the treatment of advanced prostate cancer.

IMPORTANT SAFETY INFORMATION

- Do not receive FIRMAGON if you are allergic to degarelix or any of the ingredients in FIRMAGON.
- FIRMAGON can cause serious side effects.





Important Safety Information (continued)

Serious allergic reactions. Get medical help right away if you get any of these symptoms:

- Trouble breathing or wheezing
- Severe itching
- Swelling of your face, lips, mouth, or tongue

Disorders of the heart's electrical activity. Your healthcare provider may do tests during treatment with FIRMAGON to check your heart for a condition called long QT syndrome.

- Women who are pregnant or may become pregnant should not take FIRMAGON. FIRMAGON can harm an unborn baby when given to a pregnant woman.
- Before receiving FIRMAGON, tell your healthcare provider about all your medical conditions, including if you have any heart problems including a condition called long QT syndrome, have problems with blood levels such as sodium, potassium, calcium, and magnesium, have kidney or liver problems.



AN INTRODUCTION TO YOUR FIRMAGON THERAPY

Together with your doctor, you chose FIRMAGON (degarelix) as the androgen deprivation therapy (ADT) that's right for you to treat your advanced prostate cancer (APC). FIRMAGON is a gonadotropin-releasing hormone (GnRH) antagonist¹ that has been chosen for men just like you.

This guide is designed to provide general information on APC and FIRMAGON. You can use this information during discussions with your treatment team to learn more about APC, some of the important ways your doctor will evaluate your progress during each monthly visit, and FIRMAGON, your APC therapy. Remember to always stay active and involved with your treatment team. There is a lot of information to know, and we want you to be informed and supported each step of the way.

Important Safety Information (continued)

 The common side effects of FIRMAGON include: hot flashes, injection site pain, redness and swelling, weight loss or gain, increase in some liver enzymes, decreased sex drive, and erectile function problems.

Tell your healthcare provider if you have any side effects that bother you or that does not go away. These are not all the possible side effects.



UNDERSTANDING APC: IMPACT ON YOUR DIAGNOSIS

Testosterone matters in treating APC

You may find it useful to learn some basic facts about APC. Understanding the disease more will help with the decisions you will need to make together in the future.

- Growth and function of the prostate gland depend on testosterone (T), a male hormone (or androgen) made mainly in the testicles²
- Testosterone is a hormone that can stimulate prostate cancer growth²
- Cancer of the prostate gland develops when cells of the prostate show uncontrolled growth—frequently fueled by high levels of testosterone²
- The goal of androgen deprivation therapy (ADT) is to stop the production or effects of testosterone in prostate cancer, which should then lower prostate-specific antigen (PSA) levels³
- FIRMAGON starts lowering **T** from Day 1^{1,4}

Important Safety Information (continued)

- Do not receive FIRMAGON if you are allergic to degarelix or any of the ingredients in FIRMAGON.
- FIRMAGON can cause serious side effects.

Serious allergic reactions. Get medical help right away if you get any of these symptoms:

- Trouble breathing or wheezing
- Severe itching
- Swelling of your face, lips, mouth, or tongue

How FIRMAGON works

HOW FIRMAGON WORKS

Your treatment team understands the important benefit of ADT is its ability to reduce testosterone (**T**) in your body, which is why they choose FIRMAGON.

FIRMAGON is a GnRH antagonist that immediately stops ${f T}$ production at its main source, eliminating the possibility of an initial increase in ${f T}$. For example, agonists, like leuprolide, first stimulate and increase ${f T}$ levels, which can result in the need for additional medicine to stop that effect.²

FIRMAGON helps you avoid the cost of additional medicines that are used to counteract the initial rise in testosterone with agonists.¹

Important Safety Information (continued)

Disorders of the heart's electrical activity. Your healthcare provider may do tests during treatment with FIRMAGON to check your heart for a condition called long QT syndrome.

• Women who are pregnant or may become pregnant should not take FIRMAGON. FIRMAGON can harm an unborn baby when given to a pregnant woman.



In the treatment of advanced prostate cancer (APC)

FIRMAGON takes a more direct path to testosterone suppression than leuprolide

Time to testosterone treatment goal1

ment goal¹ Time to testosterone treatment goal¹

1 TO 3 DAYS

Day 1 = 52% reached their treatment goal Day 3 = 96% reached their treatment goal

By day 28, both groups were similar

UP TO 28 DAYS

By day 28, both groups were similar

FIRMAGON is an antagonist¹

FIRMAGON is a gonadotropinreleasing hormone (GnRH) antagonist that stops testosterone suppression more directly at its main source, eliminating the possibility of an initial testosterone "surge" and any need for additional therapies to counteract surges.

FIRMAGON is a gonadotropinreleasing hormone (GnRH) antagonist available in the United States for the treatment of advanced prostate cancer (APC).

Leuprolide is an agonist^{2,5}

Leuprolide triggers a receptor called the luteinizing hormone-releasing hormone (LHRH) receptor, which results in an initial surge in testosterone. This initial surge subsequently reduces over a few weeks until **T** is suppressed. Additional medication may be required to prevent the effects of the testosterone surge.

Important Safety Information (continued)

 Before receiving FIRMAGON, tell your healthcare provider about all your medical conditions, including if you have any heart problems including a condition called long QT syndrome, have problems with blood levels such as sodium, potassium, calcium, and magnesium, have kidney or liver problems.

FIRMAGON DROPS T FAST

The goal of ADT therapy is to drop testosterone levels, and with your FIRMAGON treatment, you won't have to wait to get to this goal. Most patients on FIRMAGON reached their testosterone goal in **1 to 3 days**.¹

 By day 28 of treatment, both FIRMAGON and leuprolide achieve equivalent testosterone levels¹ (see page 9)

96% of FIRMAGON patients reached goal testosterone levels by day 3.5

Study design: In a controlled trial of FIRMAGON compared to leuprolide, FIRMAGON was shown to reduce and maintain testosterone levels below castration level (50 ng/dL) throughout the full 12-month study.6




Important Safety Information (continued)

 The common side effects of FIRMAGON include: hot flashes, injection site pain, redness and swelling, weight loss or gain, increase in some liver enzymes, decreased sex drive, and erectile function problems.



Reaching your treatment goal on FIRMAGON

T Levels in the First 14 Days of Therapy⁴



FIRMAGON (N=207)

■ Leuprolide (N=201)

BY DAY 28, BOTH FIRMAGON AND LEUPROLIDE ACHIEVED SIMILAR TESTOSTERONE LEVELS.¹

FIRMAGON **dropped T** by 88%, 94%, 96%, 97%, and 98% on day 1, 3, 7, 14, and 28, respectively.⁴

Leuprolide **increased T** by 43%, 65%, and 8% on day 1, 3, and 7, respectively, and **dropped T** by 75% and 97% on day 14 and 28, respectively.^{4}


Important Safety Information (continued)

Tell your healthcare provider if you have any side effects that bother you or that does not go away. These are not all the possible side effects.

PSA LEVELS ARE IMPORTANT TO UNDERSTAND

- Prostate-specific antigen (PSA) is a protein produced by cells in the prostate gland7*
- When PSA levels are high, it can be due to prostate cancer or other noncancerous conditions7
- PSA is used to help diagnose and track the progress of your APC treatment, so you will likely have regular tests to check your PSA level8

While no particular PSA level is considered "normal" or "abnormal," these classifications are often used^{7,9}





FIRMAGON DROPPED PSA LEVELS

- Testosterone levels can affect PSA levels
- FIRMAGON reduced median PSA levels by 64% by week 2. 85% by month 1, and 95% by month 31
- FIRMAGON is proven to maintain PSA suppression through 12 months of treatment1
 - Therefore, PSA levels should not be seen on their own as evidence of the effectiveness of FIRMAGON

PSA Levels After Starting Treatment¹



Important Safety Information (continued)

- Do not receive FIRMAGON if you are allergic to degarelix or any of the ingredients in FIRMAGON.
- FIRMAGON can cause serious side effects.

Serious allergic reactions. Get medical help right away if you get any of these symptoms:

- Trouble breathing or wheezing
- Severe itching
- Swelling of your face, lips, mouth, or tongue

^{*}PSA is a measure that may indicate that your prostate cancer has gotten worse. These results, which show a reduction of PSA, should be interpreted carefully. There is no proof that how quickly PSA drops has clinical benefit.1

RECEIVING FIRMAGON

FIRMAGON is given in your doctor's office monthly (every 28 days) in a deep subcutaneous (below the skin) injection in the abdomen. Your doctor should change the place in your abdomen where the injection is given on each visit.¹

 The first month you will get your starting dose of FIRMAGON, which will be 2 injections (120 mg each)


 After the first month, you will get a single, smaller (80 mg) injection every 28 days

 If you are pleased with the results of your monthly FIRMAGON treatment, tell your doctor you would like to stay on FIRMAGON

FIRMAGON®

120 ma, 80 ma

(degarelix for injection)



How FIRMAGON works in your body

After you receive your FIRMAGON injection, you may notice a small lump under your skin (also called a depot).¹ This depot is how your body gets a continuous supply of FIRMAGON delivered over time.

Come prepared for your injection¹



 Wear comfortable, loose-fitting clothes that won't rub against your skin



 Make sure that your belt or waistband does not rub against the injection site

Important Safety Information (continued)

Disorders of the heart's electrical activity. Your healthcare provider may do tests during treatment with FIRMAGON to check your heart for a condition called long QT syndrome.

- Women who are pregnant or may become pregnant should not take FIRMAGON. FIRMAGON can harm an unborn baby when given to a pregnant woman.
- Before receiving FIRMAGON, tell your healthcare provider about all your medical conditions, including if you have any heart problems including a condition called long QT syndrome, have problems with blood levels such as sodium, potassium, calcium, and magnesium, have kidney or liver problems.

POSTINJECTION TIPS

Everyone reacts differently to medication, and you may have some discomfort. Most people who have a reaction notice that it disappears about 3 days after the dose.

Simple ways to take care of the injection site

- Keep your injection site clean
 - Use a cool washcloth to clean the area gently, and do not scrub: pat the site gently to dry
- Avoid rubbing or scratching your abdomen where you received the injection
- Apply ice or wet, cold compresses to the injection site to reduce any pain or swelling
- Discuss taking over-the-counter pain medicine such as acetaminophen or ibuprofen, if needed, with your treatment team

Important Safety Information (continued)

• The common side effects of FIRMAGON include: hot flashes, injection site pain, redness and swelling, weight loss or gain, increase in some liver enzymes, decreased sex drive, and erectile function problems.

Tell your healthcare provider if you have any side effects that bother you or that does not go away. These are not all the possible side effects.



After your treatment

As with any ADT, you may experience some side effects. Some of the most common are below.

Common side effects of FIRMAGON¹


- Hot flashes
- Injection site pain
- Redness and swelling
- Weight loss or gain
- Increase in some liver enzymes
- Decreased sex drive
- Erectile function problems

These are not all the possible side effects. For more information, ask your healthcare provider or pharmacist. For full side effects, please see the safety information throughout this brochure.

Tell your healthcare provider if you have any side effects that bother you or that do not go away.

You may report side effects to the FDA at 1-800-FDA-1088.

Don't forget! Ask your treatment team any questions before you leave and set up your next monthly visit.



HAVE A VOICE IN YOUR TREATMENT SELECTION AND TRACK YOUR PROGRESS ON FIRMAGON

One of the most important parts of this APC journey is keeping track of your treatment and your progress. Your family and loved ones may be helping you with some aspects of your care, but it's always best for you to have a strong voice and to be your own advocate in all things related to your health.

The materials here can help organize and manage the information you receive from your doctor. And it will also be helpful in noting some questions every month when you connect with your treatment team.

Appointment dates

Be sure to schedule your next appointment before you leave the office. If you forget or miss your appointment, talk to your treatment team to reschedule as soon as possible.


Here are some questions for you to add to the notes section in your tracker. The questions may get you thinking about others to ask your treatment team.

- > What is the main goal of ADT?
- > How is FIRMAGON different than other therapies?
- > What is the duration of treatment with FIRMAGON?
- > What's the best way to keep in contact with my treatment team to get progress updates?
- > If FIRMAGON is working, can I stay on therapy?

MONTHLY MATTERS

Every month is an opportunity for you to connect with your treatment team. Make monthly visits matter by getting involved in your treatment plan.

Appointment tracker





18

PROSTATE CANCER SUPPORT FOR PATIENTS

Many resources are available to assist you.

Tools on the website were designed to help you better navigate your APC journey.

There you will find detailed information about APC, additional treatment tools, and much more.

Visit the URL below to download your PSA and Testosterone Tracker.



As part of your treatment, you may have both your Testosterone (T) and prostate specific antigen (PSA) levels measured regularly. You and your doctor can monitor these levels to evaluate how your treatment is working.

Learn more at www.FIRMAGON.com/prostate-cancer-support

STAY IN TOUCH WITH YOUR TREATMENT TEAM AND LET YOUR VOICE BE HEARD



Learn more at www.FIRMAGON.com

FIRMAGON® (degarelix for injection) is a prescription medicine used in the treatment of advanced prostate cancer.

Important Safety Information (continued)

- Do not receive FIRMAGON if you are allergic to degarelix or any of the ingredients in FIRMAGON.
- FIRMAGON can cause serious side effects.

Please see accompanying full Prescribing Information and additional Important Safety Information throughout this piece.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

You may also contact Ferring Pharmaceuticals Inc. at 1-888-FERRING.

References: 1. FIRMAGON [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 2. Gomella L.G. Effective testosterone suppression for prostate cancer: Is there a best castration therapy? Rev Urol. 2009;11(2):52-60. 3. American Cancer Society. Hormone therapy for prostate cancer. https://www.cancer.org/cancer/prostate-cancer/treating/hormone-therapy.html#whenishormonetherapyused. Accessed March 8, 2023. 4. Data on file. Ferring Pharmaceuticals Inc. 5. LUPRON DEPOT [package insert]. North Chicago, IL: AbbVie Inc. 6. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-1538. 7. American Cancer Society. Prostate cancer early detection, diagnosis, and staging: Finding prostate cancer early. https://www.cancer.org/content/dam/CRC/PDF/Public/8795.00.pdf. Accessed March 21, 2023. 8. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer V.1.2023. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed March 30, 2023. 9. National Cancer Institute. Prostate-specific antigen [PSA] test. https://www.cancer.gov/types/prostate/psa-fact-sheet. Accessed March 16, 2023.



